Anti-Human Siglec-3/CD33 Reference Antibody (BI 836858, RUO) (HB185076)

Name: Anti-Human Siglec-3/CD33 Reference Antibody (BI 836858, RUO)
Brand: abinScience
SKU: HB185076
Price: 370 USD
Availability: InStock

Fiche technique Partager le produit Copier les informations

Prix(USD) :

Spécification :

100ug
1mg
5mg
10mg
25mg
50mg
100mg

Nombre :

Contactez-nous

Aperçu
Images
Reférences
Fiche technique
SDS

Aperçu

Numéro de catalogue	HB185076
Reactivité des espèces	Human
Applications	ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Espèce hôte	Human
Clonalité	Monoclonal
Isotype	IgG1-kappa
ID de clone	BI 836858
Activité biologique	BI-836858 (10 ug/mL; 30 min) mediates specific ADCC activity against primary AML blasts [1]. BI-836858 (2 ug/mL; 4 h) mediates NK cell-dependent ADCC activity against CD33-positive HL60 cells [2]. BI-836858 (2 ug/mL; 48 h) blocks the CD33-mediated inhibitory signaling pathway in MDS bone marrow cells and reduces the expression of IL-10 and TGFβ [2]. BI-836858 (2 ug/mL) specifically blocks CD33 (S100A9)-mediated ROS production in U937 cells, healthy PBMCs, and primary MDS BM HSPCs [2]. BI-836858 (2 ug/mL; 14 days) restores the hematopoietic colony-forming capacity in ex vivo cultures of primary MDS bone marrow specimens [2].
Système d'expression	Mammalian cells
Cible	Myeloid cell surface antigen CD33, Sialic acid-binding Ig-like lectin 3, Siglec-3, CD33, gp67, SIGLEC3
Niveau d'endotoxines	< 10 EU/mg
Pureté	>95% purity as determined by SDS-PAGE.
Purification	Protein A/G purified from cell culture supernatant.
Numéro d'accès	P20138
Forme	Liquid
Tampon de stockage	0.01M PBS pH 7.4 Reférez-vous aux informations spécifiques sur le tampon dans la copie papier du datasheet ou dans le COA spécifique au lot.
Stabilité et stockage	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Noms alternatifs	BI-836858, BI836858, BI836858
Contexte	Myeloid cell surface antigen CD33 is a ~39 kDa protein. Sialic-acid-binding immunoglobulin-like lectin (Siglec) that plays a role in mediating cell-cell interactions and in maintaining immune cells in a resting state. Preferentially recognizes and binds alpha-2,3- and more avidly alpha-2,6-linked sialic acid-bearing glycans. Upon engagement of ligands such as C1q or syalylated glycoproteins, two immunoreceptor tyrosine-based inhibitory motifs (ITIMs) located in CD33 cytoplasmic tail are phosphorylated by Src-like kinases such as LCK. These phosphorylations provide docking sites for the recruitment and activation of protein-tyrosine phosphatases PTPN6/SHP-1 and PTPN11/SHP-2. In turn, these phosphatases regulate downstream pathways through dephosphorylation of signaling molecules. CD33 is the therapeutic target of gemtuzumab ozogamicin (Mylotarg). 1. Vitale, C. et al. (1999) Proceedings of the National Academy of Sciences of the United States of America 96, 15091-6. PMID: 10611343 2. Vitale, C. et al. (2001) Proceedings of the National Academy of Sciences of the United States of America 98, 5764-9. PMID: 11320212 3. Lajaunias, F. et al. (2005) European journal of immunology 35, 243-51. PMID: 15597323 4. Freeman, SD. et al. (1995) Blood 85, 2005-12. PMID: 7718872 5. Paul, SP. et al. (2000) Blood 96, 483-90. PMID: 10887109 6. Son, M. et al. (2017) Scientific reports 7, 270. PMID: 28325905 7. Taylor, VC. et al. (1999) The Journal of biological chemistry 274, 11505-12. PMID: 10206955 8. Ulyanova, T. et al. (1999) European journal of immunology 29, 3440-9. PMID: 10556798
Reférences	1. Gopalakrishnan B, et al. Polo-like kinase inhibitor volasertib marginally enhances the efficacy of the novel Fc-engineered anti-CD33 antibody BI 836858 in acute myeloid leukemia. Oncotarget. 2018;9(11):9706-9713. Published 2018 Jan 3. [HB185076] 2. Eksioglu EA, et al. Novel therapeutic approach to improve hematopoiesis in low risk MDS by targeting MDSCs with the Fc-engineered CD33 antibody BI 836858. Leukemia. 2017;31(10):2172-2180. [HB185076]
Note	For research use only. Not suitable for clinical or therapeutic use.
Isotype Control	Human IgG1 Recombinant Isotype Control Antibody (13R4) (HV080507)